Is Bioidentical Hormone Replacement Therapy Safe?
What the Updated Evidence Means for Your Options
Bioidentical hormone replacement therapy safety has been substantially re-evaluated by the FDA and independent expert bodies. This page reviews what changed, who the updated evidence applies to, and what BHRT looks like at a naturopathic clinic in Toronto.
By Dr. Fiona McCulloch, ND, FABNE, author of 8 Steps to Reverse Your PCOS and peer reviewer of the 2023 International PCOS Guidelines.
For many women in perimenopause and menopause, the decision about hormone replacement therapy has felt frozen for over two decades. The safety warnings issued after the 2002 Women’s Health Initiative were serious, widely reported, and, for most women, reason enough to avoid HRT entirely. Since November 2025, the scientific foundation of those warnings has been formally re-evaluated. This page is here to help you understand what changed and whether it’s relevant to your situation.
Book a Consultation Explore our menopause program →Approximately 50 million women have avoided hormone replacement therapy because of the safety warnings that followed the 2002 WHI study. If you’re one of them, you made a careful decision based on the best guidance available at the time. That guidance has now been revised, not by a single clinic or advocacy group, but by the FDA’s own expert advisory panel, following a comprehensive review of evidence that has accumulated over the last two decades. Reconsidering your position in response to updated evidence isn’t a reversal. It’s exactly what an informed decision looks like.
These are some of the concerns women commonly bring to an initial consultation after years of managing on their own:
- Hot flashes and night sweats that disrupt daily routines and sleep
- Sleep fragmentation that persists regardless of sleep hygiene measures
- Cognitive changes: difficulty with focus, word-finding, or mental clarity
- Mood shifts, increased irritability, or a sense of emotional flatness
- Vaginal dryness and changes in tissue integrity
- Muscle and joint pain that appeared or worsened during perimenopause
If any of these are part of your experience, you’re not navigating this alone. The science that discouraged treatment for these symptoms has been substantially updated. Choosing to re-examine your options based on new evidence is the intelligent response, not a contradiction of the caution you exercised before.
HRT Black Box Warnings: What They Were and Why They're Being Removed
In 2002, the Women’s Health Initiative (WHI), a large randomized trial, reported increased risks of breast cancer and cardiovascular events in women using hormone replacement therapy. The findings led the FDA to apply black box warnings to all HRT products, and prescribing rates dropped sharply. For two decades, these warnings shaped how women and their healthcare providers approached menopause treatment. But the study that produced them had significant limitations that only became fully clear as the data was re-examined.
The WHI study primarily involved older women (average age 63) using synthetic hormones, specifically conjugated equine estrogens and medroxyprogesterone acetate, not bioidentical hormones. Most participants had been postmenopausal for years, well beyond the typical window when HRT is now considered. If you are in perimenopause or early menopause, you are not the population the WHI studied. The distinction between synthetic hormones given to older women and bioidentical hormones given to women within the appropriate timing window is the foundation of the re-evaluation that has taken place.
What the FDA's November 2025 Decision Found
In November 2025, an FDA expert advisory panel completed its review of the accumulated evidence on hormone replacement therapy and recommended removing the black box warnings from HRT products. This recommendation followed multiple independent research findings:
- Manson JE et al. (2025) reported that women who began estrogen-alone therapy in early menopause showed lower breast cancer incidence over the 20-year follow-up period, a reversal of the original WHI headline
- The Menopause Society (2025) reviewed the cardiovascular evidence and found a favourable risk profile for women initiating HRT within 10 years of menopause onset or before age 60
- The FDA’s updated labeling reflects that the blanket warnings no longer accurately represent the current evidence base
In Canada, Health Canada has not yet issued identical labeling changes, but the regulatory direction aligns with the updated international evidence. The clinical guidelines used by practitioners in Ontario already reflect this re-evaluation.
Bioidentical vs. Synthetic Hormones: A Structural Distinction
Bioidentical hormones (such as estradiol, progesterone, and testosterone) are structurally identical to the hormones naturally produced in the human body. They are typically synthesized from plant sources (yams or soy). The synthetic hormones used in the WHI study (conjugated equine estrogens derived from horse urine and medroxyprogesterone acetate) are structurally different molecules. These are not interchangeable categories. Research findings from one do not automatically transfer to the other, and the updated evidence reflects this distinction.
What Bioidentical Hormone Replacement Therapy Involves
Bioidentical hormone replacement therapy (BHRT) uses hormones that match the molecular structure of those your body produces naturally. The most commonly prescribed bioidentical hormones are estradiol, progesterone, and, in some protocols, testosterone. These are available in several delivery forms, including transdermal patches, oral capsules, topical creams and gels, and vaginal suppositories. The delivery method is selected based on clinical considerations and patient preference.
Pharmaceutical-Grade BHRT
Pharmaceutical-grade bioidentical hormones are manufactured by licensed pharmaceutical companies and available by prescription at standard pharmacies. They come in pre-set dose increments. Prescriptions are often covered by standard prescription insurance plans, the same coverage that applies to other prescription medications.
Compounded BHRT
Compounded bioidentical hormones are prepared by a compounding pharmacy to a specific prescription. Compounding allows more precise dose customization beyond the limited increments available in pharmaceutical products. Some patients prefer compounded formulations to avoid certain fillers or additives present in pharmaceutical-grade products. Compounded prescriptions are not always covered by insurance.
Both pharmaceutical-grade and compounded bioidentical hormones are equally effective. The choice between them depends on your insurance coverage, whether a specific dose customization is needed, and your preferences around formulation. This is a patient-driven decision; your practitioner will present both options and the practical tradeoffs so you can choose what fits your situation.
For more on specific hormones used in BHRT protocols: bioidentical progesterone therapy and estriol, a bioidentical estrogen option.
Is Bioidentical HRT Right for Your Situation?
BHRT is most commonly considered for women in perimenopause or menopause who are experiencing symptoms and meet certain clinical criteria. Not every woman with menopausal symptoms is an automatic candidate; that specificity is part of a careful evaluation. Here is what practitioners typically assess:
- You are experiencing perimenopause or menopause symptoms that affect your quality of life
- You are within 10 years of menopause onset, or under age 60 (the evidence-supported timing window)
- You have no absolute contraindications (assessed individually at consultation)
- You want to understand all available options before making a decision
What About a History of Breast Cancer?
A personal or family history of breast cancer is not an automatic disqualifier for BHRT, but it is not a simple yes-or-no question either. Hormone receptor status is a key factor in the individual evaluation. Whether a prior cancer was estrogen-receptor positive or negative changes the clinical picture significantly. Family history, particularly when there is a known genetic component, is also evaluated individually. For women with a cancer history, the assessment is always done in collaboration with your oncologist or GP. The goal is a thorough, individualized evaluation, not a blanket exclusion and not a blanket reassurance. Bring your full history to the initial consultation; the answer depends on specifics that cannot be generalized on a webpage.
Testing is not required before starting BHRT. Many women assume they need bloodwork or hormone panels before they can begin, and that assumption can delay care. Treatment can begin based on your symptoms and clinical timeline. Testing is available and helpful for optimizing a protocol, but it is not a prerequisite. Many women find that symptoms like hot flashes and sleep disruption begin to shift within a month of starting treatment. Testing can be added at any point.
If this sounds relevant to your situation, an initial consultation is the next step: a conversation about your symptoms, your history, and what options would make sense for you.
Book a ConsultationCommon Questions About Bioidentical Hormone Replacement Therapy
These are questions we hear regularly from women who are researching BHRT for the first time or reconsidering it after years of avoidance. Each answer reflects the current evidence base and our clinical approach.
Safety
I've heard that HRT causes breast cancer. Does that apply to bioidentical hormones?
The breast cancer concern originated from the 2002 WHI study, which used synthetic conjugated equine estrogens and medroxyprogesterone acetate in a cohort of older women (average age 63) who were well past the typical window for starting HRT. Bioidentical estradiol is a structurally different molecule from the synthetic estrogens studied in that trial. In the 20-year WHI follow-up data, Manson et al. (2025) reported that women who began estrogen-alone therapy in early menopause actually showed lower breast cancer incidence, a finding that directly contradicts the original headline. The evidence does not support applying the WHI’s breast cancer findings to bioidentical hormones used in appropriate candidates within the evidence-supported timing window. Your individual situation, including personal and family cancer history, would be evaluated at a consultation.
What exactly changed with the HRT black box warning? When was it removed?
In November 2025, an FDA expert advisory panel reviewed the accumulated evidence on hormone replacement therapy and recommended removing the black box warnings that had been applied to HRT products since the early 2000s. The panel concluded that the blanket warnings no longer accurately reflected the current evidence base. The updated labeling was issued by the FDA in the same month. In Canada, Health Canada has not yet issued identical changes, but Ontario clinical guidelines already reflect the updated international evidence. The FDA’s decision is described in detail on HHS.gov.
I have a history of breast cancer (or a strong family history). Can I still consider BHRT?
A cancer history does not automatically exclude someone from BHRT, but it does require a more individualized evaluation. Hormone receptor status is the key clinical factor. Whether a prior cancer was estrogen-receptor positive or negative significantly changes the assessment. Family history, especially when there is a known genetic component, is also evaluated on a case-by-case basis. We always work collaboratively with your oncologist or GP to ensure any approach is safe and appropriate for your specific situation. This is assessed at the initial consultation with your full medical history; the answer genuinely depends on individual factors that cannot be generalized.
What about blood clots and cardiovascular risk? Wasn't that part of the original warnings?
Cardiovascular risk was a finding in the WHI’s older, synthetic-hormone cohort, the same population context described above. The Menopause Society’s 2025 review found a favourable cardiovascular profile for women who begin HRT within 10 years of menopause onset or before age 60. Delivery method also matters: transdermal (topical) routes (patches, creams, and gels) have a different absorption profile than oral routes, which is relevant to clotting risk. Your cardiovascular history, timing, and preferred delivery method are all part of what’s evaluated at a consultation. No blanket statement applies here; this is assessed individually.
Candidacy
How do I know if I'm a good candidate for BHRT?
The strongest evidence base for BHRT applies to women in perimenopause or menopause who are experiencing symptoms and are within 10 years of menopause onset or under age 60. That said, candidacy is not a checklist you complete on your own; it’s exactly what the first appointment evaluates. If you’re experiencing symptoms and wondering whether BHRT is appropriate, that question is the reason consultations exist. Your practitioner will review your symptoms, timeline, medical history, and goals to determine which options, if any, make sense for your situation.
Do I need to get bloodwork or hormone testing done before my first appointment?
No. Testing is not required to start hormone replacement therapy. Treatment can begin based on your symptoms and clinical timeline; we can assess candidacy and initiate a protocol without waiting for lab results. Testing is available and is always preferable when possible, because it helps optimize the protocol. But it is not a prerequisite, and waiting for labs should not be a barrier to getting started. Many women find that symptoms like hot flashes and sleep disruption begin to shift within a month of starting BHRT. Testing can be added at any point in the process.
My GP told me HRT is risky and advised against it. Are you contradicting my doctor?
Many women in this situation have had this conversation with a GP or OB/GYN; it’s one of the most common things we hear. The clinical landscape around HRT has changed substantially since the original 2002 warnings were issued. The FDA’s November 2025 reassessment reflects updated evidence reviewed by an independent expert panel, and many of the concerns your GP may have referenced are based on data from the older WHI cohort that does not apply to most women now considering BHRT. A naturopathic consultation provides a second perspective, not to replace your GP, but to review the current evidence with you and ensure you have the full picture. If you decide to proceed, we communicate with your existing care team as appropriate.
Process and Access
Can a naturopath actually prescribe bioidentical hormones? Is this regulated?
Yes. Licensed naturopathic doctors (NDs) in Ontario have regulated prescribing authority for bioidentical hormones under the College of Naturopaths of Ontario (CONO). This is within the authorized scope of practice for Ontario NDs, not a workaround or an off-label arrangement. BHRT prescriptions issued by an ND are filled at standard pharmacies and compounding pharmacies, the same as any other prescription.
What's the difference between pharmaceutical-grade and compounded BHRT? Which is better?
Both are equally effective. The practical differences come down to insurance, dose customization, and formulation preferences. Pharmaceutical-grade BHRT comes in pre-set dose increments and is often covered by standard prescription insurance. Compounded BHRT is prepared by a compounding pharmacy to your specific prescription, which allows more precise dose customization, useful when the available pharmaceutical doses don’t match what you need. Some patients also prefer compounded formulations to avoid certain fillers or additives. Neither option is inherently superior. Your practitioner will explain the tradeoffs and you choose what works best for your priorities.
Will I be steered toward a particular treatment or produc
No. The consultation is a conversation; the goal is to present all available options, explain the evidence behind each one, and let you make the choice that fits your situation. We have access to the full range of available approaches: pharmaceutical-grade and compounded, with or without testing, all available delivery forms. We’re not going to push you toward any particular one. What we are going to do is make sure you have all the information about your body and the different options available to you, the safest ones and the most effective ones, so you can make a decision you feel confident about.
What will it cost? Is BHRT covered by insurance?
Pharmaceutical-grade BHRT prescriptions are often covered by standard prescription insurance plans, the same coverage that applies to other prescription medications. Compounded preparations are not always covered. Consultation fees and full program details are outlined on our menopause program page.
I've tried other approaches for my menopause symptoms and nothing has worked. How is this different?
Many women arrive at our clinic after navigating a range of approaches: supplements, lifestyle modifications, waiting it out, or general-purpose prescriptions that didn’t quite fit. An individualized hormonal evaluation is different from a generalized approach because it starts with your specific symptom picture and clinical history, not a default protocol. Women who’ve tried other approaches and not found relief often benefit from a more thorough assessment that identifies what’s actually driving their symptoms and matches treatment to that picture specifically.
What Your First Visit Looks Like
Your first appointment is a conversation, not a commitment. You don’t need to have made any decisions before coming in, and you don’t need to bring test results.
1
Initial consultation
We discuss your symptoms, timeline, health history, and what you're hoping to understand. If you'd like hormone testing, we can arrange it, but it's not required to get started.
2
Review your options
All available approaches are presented: pharmaceutical-grade and compounded, different delivery forms, with or without testing. Your practitioner explains the evidence and tradeoffs for each. You drive the decision.
3
If you decide to proceed
A prescription is issued. Insurance coverage for pharmaceutical-grade products is reviewed at this stage.
4
Follow-up at 4–6 weeks
We assess your response, discuss any adjustments, and refine the protocol as needed.
5
Ongoing monitoring
Regular follow-up is part of the standard of care; your practitioner monitors your response and adjusts over time.
Timeline: Many women find that symptoms like hot flashes and sleep disruption begin to shift within a month of starting BHRT. Musculoskeletal symptoms (such as joint pain and stiffness) may take longer. Your practitioner will monitor your response and adjust as needed.
Pharmaceutical-grade BHRT prescriptions are often covered by standard prescription insurance. Compounded prescriptions are not always covered. Consultation fees and full program details are available on our menopause program page. Full details on fees and insurance →
Meet our Practitioners
Both Dr. Fiona and Dr. Alex see PCOS patients at White Lotus Clinic using the same clinical framework. Fees differ by practitioner.
Fees for Dr Alexandra Triendl-Dimitriu, ND
Perimenopause care using the same clinical framework as Dr. Fiona. For complex or challenging cases, Dr. Alex has direct access to Dr. Fiona's guidance — so you benefit from that depth of expertise regardless of which practitioner you see.
| Time | Description | Price |
|---|---|---|
| Up to 90 mins | Initial Naturopathic Consultation | $350 |
| 30m | Followup Naturopathic Consultation | $110 |
Fees for Dr Fiona McCulloch, RAc, ND
Author of 8 Steps to Reverse Your PCOS. Treating Menopause for 20+ years with a clinical focus in hormonal health, thousands of patients assessed.
| Time | Description | Price |
|---|---|---|
| Up to 90 min | Initial Naturopathic Consultation | $420 |
| 45m | Followup Naturopathic Consultation | $215 |
Click Links in description to see booking options. All new patents must start with an initial consultation.
Dr. Fiona McCulloch is a naturopathic doctor and the founder of White Lotus Clinic in Toronto. Her clinical focus is hormone health, with over 20 years of practice.
- Board certified: Fellow of the American Board of Naturopathic Endocrinology (FABNE)
- Author of 8 Steps to Reverse Your PCOS (Greenleaf Publishing)
- Peer reviewer of the 2023 International Evidence-Based PCOS Guidelines
- Board member of the Endocrinology Association of Naturopathic Physicians (EndoANP) from 2018-2026
Insurance Coverage
Insurance is not provided by OHIP but is typically included on most extended insurance plans.
Prescribing note
Licensed naturopathic doctors (NDs) in Ontario have regulated prescribing authority for bioidentical hormones under the College of Naturopaths of Ontario (CONO). This is an authorized scope of practice, not an alternative pathway or a workaround. BHRT prescriptions issued by Ontario NDs are filled at standard pharmacies and compounding pharmacies. Naturopathic menopause care, including hormone prescribing, is a regulated option in Ontario.
Getting here
Location
121 Willowdale Ave Suite 301
Toronto / North York, Ontario M2N 6A3
Located near Yonge & Sheppard.
Clinic Hours
| Monday | 9:00 AM – 5:00 PM |
| Tuesday | 9:00 AM – 5:00 PM |
| Wednesday | 9:00 AM – 5:00 PM |
| Thursday | 9:00 AM – 7:00 PM |
| Friday | 9:00 AM – 5:00 PM |
| Saturday | 9:00 AM – 4:30 PM |
| Sunday | Closed |
Located in North York, Toronto.
Transit and parking:
3-minute walk from Sheppard–Yonge Station
3 minute drive from the Highway 401 Bayview exit by car
Street parking available
Accessibility:
Elevator access
Entrance Ramp
Please contact us if accommodations are needed.
Our Consultation Philosophy
We’re not going to push you toward any particular option. What we are going to do is make sure you have all the information about your body, your options, and what would make sense for your specific situation. We’re here to be a guide for you through that process.
Women who have been researching HRT often arrive having already been sold to by wellness brands, supplement marketers, or well-meaning but outdated medical advice. Our approach is different. A consultation at White Lotus is a clinical conversation: we learn what you’re experiencing, we present the full range of available options and the evidence behind each one, and you make the decision that works for you. No protocol is being promoted. No option is off the table.
Aligned With Updated Expert Guidance
If you’ve been reconsidering hormone replacement therapy after years of avoiding it, an initial consultation is the next step, not to be pushed toward a decision, but to review your individual picture with a practitioner who can put all the options on the table. You don’t need bloodwork, you don’t need a referral, and you don’t need to have made up your mind. The consultation is a conversation about your symptoms, your history, and what might make sense for you.
Book a BHRT Consultation in Toronto Explore our menopause program →References
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2025. doi:10.1001/jama.2017.18869
- The Menopause Society. The 2025 Menopause Society Position Statement on Hormone Therapy. Menopause. 2025.
- The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
- Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497-515. doi:10.1016/j.ecl.2015.05.001
- U.S. Food and Drug Administration. FDA Updates Hormone Therapy Labeling for Menopause. November 2025. Available at: HHS.gov.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal Risks for Breast Cancer Associated with Different Hormone Replacement Therapies: Results from the E3N Cohort Study. Breast Cancer Res Treat. 2008;107(1):103-111. doi:10.1007/s10549-007-9523-x